Effect of bortezomib regimens and daratumumab monotherapy on cellular immunity in multiple myeloma patients
Background: Treatment with Bortezomib (a proteasome inhibitor) and Daratumumab (DARA, a monoclonal anti CD38 antibody) are effective in patients with multiple myeloma (MM). However, these drugs impair cellular immunity, which may render the patients more prone to infection. Objective: To investigate...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shiraz University of Medical Sciences
2021-06-01
|
| Series: | Iranian Journal of Immunology |
| Subjects: | |
| Online Access: | https://iji.sums.ac.ir/article_47660_4170419ab063f5be3b93901a6ae1bba9.pdf |